Evotec SE (NASDAQ:EVO) Short Interest Up 104.3% in November

Evotec SE (NASDAQ:EVO) was the target of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 449,700 shares, a growth of 104.3% from the October 31st total of 220,100 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 195,200 shares, the short-interest ratio is presently 2.3 days.

Evotec Price Performance

NASDAQ:EVO traded up $0.07 during midday trading on Thursday, reaching $4.83. 145,857 shares of the stock traded hands, compared to its average volume of 134,367. The business has a 50-day moving average of $3.90 and a two-hundred day moving average of $4.19. Evotec has a 12-month low of $2.85 and a 12-month high of $12.00. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43.

Wall Street Analysts Forecast Growth

EVO has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Evotec in a research report on Thursday, November 7th. Jefferies Financial Group cut shares of Evotec from a “buy” rating to a “hold” rating and lowered their target price for the company from $8.70 to $3.80 in a research note on Monday, October 7th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Evotec from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $5.93.

Institutional Trading of Evotec

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP lifted its holdings in Evotec by 29.7% during the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company’s stock valued at $9,616,000 after purchasing an additional 602,858 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new stake in shares of Evotec during the third quarter valued at about $104,000. Mediolanum International Funds Ltd acquired a new position in shares of Evotec in the third quarter valued at approximately $512,000. Novo Holdings A S acquired a new position in shares of Evotec in the second quarter valued at approximately $71,183,000. Finally, DCF Advisers LLC grew its holdings in shares of Evotec by 140.5% in the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after purchasing an additional 67,156 shares in the last quarter. Institutional investors and hedge funds own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.